Eli Lilly and Company announced that Foundayo (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the FDA approval on April 1,… read more.
Research from Italy to be presented at this year’s European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) and published in the journal Nutrients shows that when the gold… read more.
Eli Lilly and Company announced the FDA approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased… read more.
Sticking to the same meals and eating a consistent number of calories each day may help people lose more weight, according to research published by the American Psychological… read more.
People with type 1 diabetes who took GLP-1 receptor agonist (GLP-1-RA) drugs for weight loss or better blood-sugar control had significantly reduced risks of major cardiovascular events and… read more.
The European Commission has approved a new 7.2 mg once‑weekly maintenance dose of Wegovy (semaglutide injection) for adults living with obesity. This gives doctors another option to help… read more.
Eli Lilly and Company announced that access to self-pay pricing on the new Zepbound (tirzepatide) KwikPen for single-patient use will be available at LillyDirect and major pharmacies nationwide,… read more.
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ‘eye stroke’ (ischaemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an… read more.
A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain on average 60% of their lost weight – but beyond this, their weight… read more.
Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity may also help to lower the risk of addiction to a range of substances including… read more.
Eli Lilly and Company announced the FDA approved a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen that delivers a full month of treatment… read more.
An international research group has examined how many people are affected by preclinical and clinical obesity and what health risks are associated with this. The team led by… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
